“…As shown in the example above, when an enantiomer of a useful substance exists under development, it should be verified that there is a difference in activity depending on each form. Although studies on the anti-cancer activity of ginsenoside Rh2 have been performed on lung, breast, liver, colorectal cancers, and leukemia, there has been no study of the cellular pattern of cancer cells when Rh2 was treated in real-time (Ge, Yan, & Cai, 2017;Han et al, 2016;Kim & Choi, 2016;Li, Li, Dong, Wang, & Li, 2017;Ren, Shi, Teng, & Yao, 2018;Wan et al, 2017). Among the existing studies, there is a study on how Rh2 using HCT-116 cells can act as a specific mechanism of anti-cancer activity for a colorectal cell line (Han et al, 2016).…”